More 'predictable' rules sought in Brazil to boost pharma trade
India seeks predictable regulatory pathways in Brazil to boost pharmaceutical exports. This move aims to ensure affordable and quality medicines for accessible healthcare. Both nations agreed to finalize terms for expanding the India-Mercosur trade agreement. Bilateral trade between India and Brazil reached $15.07 billion in 2025-26. The countries aim to increase this trade to $30 billion by 2030.
India has called for a more stable regulatory landscape in Brazil to promote the export of pharmaceutical products, the government announced on Monday. This move could lead to more affordable and high-quality medicines becoming available, aiding the drive for accessible healthcare, the authorities stated. At the India-Brazil Trade Monitoring Mechanism's eighth meeting in Brasilia, Brazil, advances were made in facilitating market access for Indian pharmaceutical goods, according to a statement released by the commerce and industry ministry.
India stressed the importance of promoting predictable regulatory routes and enhancing market access, it added. The two nations also reached an agreement to swiftly finalize the terms of reference for discussions to broaden the scope of the existing trade pact between India and the South American bloc Mercosur. Mercosur consists of Brazil, Argentina, Uruguay, and Paraguay.
The India-Mercosur Preferential Trade Agreement came into force on June 1, 2009. With bilateral trade between India and Brazil reaching $20.84 billion in 2025, both sides pledged to expedite the finalization of the terms of reference. The two countries have also pledged to elevate trade to $30 billion by 2030.
Written by urgent.news from The Economic Times - Economy's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
